- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT04876053
Dostawa żywności do domu w leczeniu cukrzycy u pacjentów poradni wiejskich
Naszym długoterminowym celem jest przekształcenie zarządzania T2DM przez mieszkańców wsi. Celem tego badania jest określenie skuteczności interwencji, która jest skalowalna i zrównoważona oraz promuje przestrzeganie zaleceń przez pacjentów poprzez łagodzenie trudności uczestników wiejskich, którzy nie mają bezpieczeństwa żywnościowego, związanych z ukończeniem istniejących interwencji. Nasze cele szczegółowe to:
- Porównanie skuteczności interwencji w zakresie dostarczania zdrowej żywności (HFDI) oraz standardowej opieki i samej standardowej opieki w celu poprawy wyników związanych z cukrzycą wśród wiejskich pacjentów z T2DM, którzy nie mają bezpieczeństwa żywnościowego. Hipoteza: W porównaniu z samą terapią standardową, pacjenci otrzymujący HFDI plus standardową opiekę wykażą poprawę: kontroli glikemii H1 mierzonej za pomocą HbA1c; H2 sercowo-metaboliczne czynniki ryzyka: ciśnienie krwi, glukoza na czczo, lipidy na czczo i BMI; H3 samokontrola: poczucie własnej skuteczności, przestrzeganie zachowań związanych z samokontrolą i przestrzeganie zaleceń lekarskich; H4 wyniki skoncentrowane na pacjencie: dystres związany z cukrzycą, jakość życia związana z cukrzycą i powikłania związane z cukrzycą.
- Porównanie skuteczności HFDI plus standardowej opieki i samej standardowej opieki w celu poprawy jakości diety wśród wiejskich pacjentów z T2DM, którym brakuje żywności. Hipoteza: W porównaniu z samym standardowym leczeniem, pacjenci otrzymujący HFDI plus standardową opiekę wykażą lepsze wyniki: H1 Healthy Eating Index 2015 (HEI-2015); H2 spożycie owoców i warzyw.
- Porównaj efektywność kosztową, aby zrozumieć HFDI plus koszty standardowej opieki w stosunku do wyników w odniesieniu do samej standardowej opieki. Hipoteza: HFDI będzie opłacalny w oparciu o tradycyjny koszt za dodatkowy uzyskany rok życia skorygowany o jakość.
Przegląd badań
Status
Warunki
Interwencja / Leczenie
Szczegółowy opis
Type 2 diabetes mellitus (T2DM) is a growing public health concern affecting 37.3 million people (11.3%) in the United States (US). At the same time, 13.5 million (10.2%) US households experience food insecurity. People living in rural areas are particularly challenged by the intersection of food insecurity and T2DM - both food insecurity and T2DM prevalence in rural areas are higher than metropolitan areas. Arkansas has the sixth highest proportion of rural population (44.5%) of all US states, with rates of food insecurity and T2DM of 14.7% and 12.5%, respectively. Rurality and food insecurity are associated with social determinants of health that impede diabetes management (e.g., limited transportation, longer distance to healthcare clinics, lack of access to healthy food options). People experiencing food insecurity have poor diet quality (e.g., high intake of sugar-sweetened beverages and red/processed meat, low intake of fruits and vegetables), which is a key risk factor for unmanaged T2DM. Unmanaged T2DM can lead to increased risk of serious complications. Improved diet quality is a crucial factor to enhance T2DM management. Millions of people with T2DM experiencing food insecurity turn to food pantries for food; however, food pantries are not a long-term solution to improve health for rural people with T2DM experiencing food insecurity. Certified Diabetes Care and Education Specialists (CDCES; i.e., diabetes educators) have expertise in working with patients to instill knowledge and skills necessary to live an active and healthy lifestyle with T2DM.
This study used a two-arm randomized controlled comparative effectiveness design to compare the effectiveness of a Healthy Food Delivery Intervention (HFDI) plus a consultation with a CDCES Consultation Only in improving diabetes-related outcomes among rural people with T2DM experiencing food insecurity. We hypothesized HFDI to be comparatively more effective in improving HbA1c and other outcomes for rural people with T2DM experiencing food insecurity.
The primary outcome was change in hemoglobin A1c (HbA1c) between baseline and post-intervention. Secondary outcomes included diet quality (Healthy Eating Index-2015 and Veggie meter scores), body mass index, blood pressure, lipids, glucose, diabetes management self-efficacy and diabetes-related distress. We also examined the duration of treatment effects by comparing outcomes at 6 months post-intervention and 12 months post-intervention.
Participants were randomly assigned to either the HFDI arm or the CDCES Consultation Only arm. Participants randomized to the CDCES Consultation Only study arm received the standard of care at the clinic from which they were recruited, plus a 60 minute healthy eating consultation with a CDCES and a food pantry resource guide specific to their community. In addition to standard of care and the CDCES consultation, participants randomized to the HFDI arm received weekly home delivery of type 2 diabetes-appropriate food boxes over 3 months (12 food boxes in total). Each food box included approximately 9000 calories of food. Food boxes were designed by a Registered Dietician. Food boxes also included recipes and cooking tips specific to foods included in that week's box.
Participants were initially recruited only from family medicine clinics within the University of Arkansas for Medical Sciences (UAMS) network that serve the highest percentage of rural patients with T2DM. Additional clinics and Federally Qualified Health Centers were added as recruitment sites in order to meet study recruitment goals.
Inclusion criteria included: 1) 18 years of age or older; 2) food insecure (Hunger Vital Sign™ 2-item screener); 3) HbA1c ≥ 6.5%; 4) speak English or Spanish; and 5) live at a rural address. Note: the food insecurity and rural residence criteria were removed during the course of the study in order to meet study recruitment goals.
Exclusion criteria included: 1) having conditions making it unlikely the participant will be able to follow the protocol, such as terminal illness, severe mental illness, severely impaired vision or hearing, eating disorder, or plans to move out of the geographic region; 2) pregnant; 3) only one adult with T2DM per household was allowed to enroll.
Investigators worked with clinical stakeholders at each clinic site to ensure the study was integrated into existing workflows. Study flyers were placed throughout the clinics, in the exam rooms, and in the clinic waiting areas. All clinics had electronic health record systems that were queried monthly for recruitment. Research coordinators at each clinic site identified potential participants by reviewing monthly patient queries and daily clinic schedules. The research coordinators provided study information to potential participants in a pre-visit call or during the clinical visit. If the patient was interested, the research coordinator scheduled a 30-minute meeting to discuss the study and conduct eligibility screening in a private room in the clinic. Research staff were trained to flag potential participants that may not meet eligibility, which were then sent to the study physician for medical determination. Those deemed eligible to participate reviewed study information with the research coordinator, were given the chance to ask questions, and signed an informed consent. All recruitment and consent information was available in English and Spanish.
Randomization was conducted by the study biostatistician, who had no interactions with potential participants and no supervisory role with study staff responsible for recruiting, consent, and intervention processes. Stratified random assignment using permuted blocks of size 2, 4, and 6 was used to randomize participants 1:1 to the treatment arms using lists created with the blockrand R package. Strata of participant sex, level of T2DM control (6.5-9.0%; >9.0%), and age group (18-64; 65+ years) were used to ensure that similar numbers within each characteristic are assigned 1:1 to the treatment arms.
Data collection occurred in-person at the clinic from which participants were recruited, co-occurring with participants' primary care provider visits when possible. Biometric and survey measure outcomes were collected at baseline (pre-intervention), immediate post-intervention (approximately 12 weeks after baseline), 6 months post-intervention, and 12 months post-intervention.
Typ studiów
Zapisy (Rzeczywisty)
Faza
- Nie dotyczy
Kontakty i lokalizacje
Lokalizacje studiów
-
-
Arkansas
-
Batesville, Arkansas, Stany Zjednoczone, 72501
- UAMS - North Central
-
Corning, Arkansas, Stany Zjednoczone, 72422
- Pocahontas Medical Center
-
Eureka Springs, Arkansas, Stany Zjednoczone, 72632
- Washington Regional Medical Center
-
Fayetteville, Arkansas, Stany Zjednoczone, 72703
- Washington Regional Medical Center
-
Fayetteville, Arkansas, Stany Zjednoczone, 72703
- UAMS - Northwest
-
Fort Smith, Arkansas, Stany Zjednoczone, 72901
- UAMS - West
-
Harrison, Arkansas, Stany Zjednoczone, 72601
- Washington Regional Medical Center
-
Helena, Arkansas, Stany Zjednoczone, 72390
- UAMS - East
-
Jonesboro, Arkansas, Stany Zjednoczone, 72401
- UAMS - Northeast
-
Magnolia, Arkansas, Stany Zjednoczone, 71753
- UAMS - South
-
Marianna, Arkansas, Stany Zjednoczone, 72360
- Lee County Cooperative Clinic
-
Marshall, Arkansas, Stany Zjednoczone, 72650
- Boston Mountain Rural Health Center
-
Pocahontas, Arkansas, Stany Zjednoczone, 72455
- Pocahontas Medical Clinic
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Opis
Kryteria przyjęcia:
- 18 lat lub więcej
- zgłosić brak bezpieczeństwa żywnościowego
- raport T2D (potwierdzony posiadaniem HbA1c równym lub większym niż 6,5 podczas wstępnego zbierania danych bezpośrednio po wyrażeniu zgody)
- Mów po angielsku lub hiszpańsku
- Obecnie mieszka pod adresem wiejskim
Kryteria wyłączenia:
- warunki uniemożliwiające uczestnikowi przestrzeganie protokołu, takie jak śmiertelna choroba, ciężka choroba psychiczna, poważne upośledzenie wzroku lub słuchu, zaburzenia odżywiania lub plany wyprowadzki z regionu geograficznego
- W ciąży
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Leczenie podtrzymujące
- Przydział: Randomizowane
- Model interwencyjny: Przydział równoległy
- Maskowanie: Podwójnie
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
|---|---|
|
Aktywny komparator: CDCES Consultation Only
Participants randomized to this study arm receive the standard of care at the clinic from which they were recruited, plus a 60 minute healthy eating consultation with a Certified Diabetes Care and Education Specialist and a food pantry resource guide specific to their community.
|
Participants randomized to this study arm receive the standard of care at the clinic from which they were recruited, plus a 60 minute healthy eating consultation with a Certified Diabetes Care and Education Specialist and a food pantry resource guide specific to their community.
|
|
Eksperymentalny: Healthy Food Delivery Intervention
In addition to standard of care and the CDCES consultation, participants randomized to the Healthy Food Delivery arm receive weekly home delivery of type 2 diabetes-appropriate food boxes over 3 months (12 food boxes in total).
|
Participants randomized to the Healthy Food Delivery Intervention receive standard of care, a CDCES Consultation, food pantry resource guide, and weekly home delivery of type 2 diabetes-appropriate food boxes over 3 months (12 food boxes in total).Each food box included approximately 9000 calories of food.
Food boxes were designed by a Registered Dietician.
Food boxes also included recipes and cooking tips specific to foods included in that week's box.
|
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Hemoglobin A1c (HbA1c)
Ramy czasowe: Baseline; Immediate post-intervention (approx. 12 weeks); 6 months post-intervention; 12 months post-intervention
|
Finger stick blood collection will be used to test HbA1c using a Siemens DCA Vantage analyzer.
|
Baseline; Immediate post-intervention (approx. 12 weeks); 6 months post-intervention; 12 months post-intervention
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Diet Quality: Healthy Eating Index-2015 Score
Ramy czasowe: Baseline; Immediate post-intervention (approx. 12 weeks)
|
Diet quality was assessed with a 24-hour dietary recall interview using the Nutrition Data System for Research (NDSR) software.
The Healthy Eating Index-2015 (HEI) was applied to the dietary recall data to measure the extent that dietary intake among participants met the Dietary Guidelines for Americans 2015-2020 recommendations.
HEI-2015 consists of 13 individual components.
HEI-2015 scores have a possible range of 0-100, with higher numbers indicating better diet quality.
|
Baseline; Immediate post-intervention (approx. 12 weeks)
|
|
Diet Quality: Veggie Meter Score
Ramy czasowe: Baseline; Immediate post-intervention (approx. 12 weeks); 6 months post-intervention; 12 months post-intervention
|
Skin carotenoid level was measured using a Veggie Meter optical skin scanner, which uses Raman Spectroscopy.
The Veggie Meter assesses frequency changes in reflected light to calculate carotenoid presence in the skin and has been validated as a non-self-report, non-invasive measure associated with serum carotenoid levels and self-report measures of fruit and vegetable consumption.
Each participant's index finger was scanned three times and the mean of the three measures was recorded for use in data analysis.
Veggie Meter scores have a possible range of 0-800, with higher scores indicating better diet quality.
|
Baseline; Immediate post-intervention (approx. 12 weeks); 6 months post-intervention; 12 months post-intervention
|
|
Body Mass Index (BMI)
Ramy czasowe: Baseline; Immediate post-intervention (approx. 12 weeks); 6 months post-intervention; 12 months post-intervention
|
Participant height (without shoes) was collected using a stadiometer and participant weight (without shoes) was collected using a calibrated digital scale.
Height and weight were used to compute a continuous measure of BMI (kilograms per square meter).
|
Baseline; Immediate post-intervention (approx. 12 weeks); 6 months post-intervention; 12 months post-intervention
|
|
Systolic Blood Pressure (SBP)
Ramy czasowe: Baseline; Immediate post-intervention (approx. 12 weeks); 6 months post-intervention; 12 months post-intervention
|
Blood pressure was measured with a digital blood pressure device with the participant seated and arm elevated to place the cuff approximately at heart height.
Two blood pressure measurements were taken, waiting at least one minute between readings.
If there was a >5mmHg difference between the first and second reading, an additional two measurements were taken.
The mean of the two (or four) measurements was recorded and used in analysis.
|
Baseline; Immediate post-intervention (approx. 12 weeks); 6 months post-intervention; 12 months post-intervention
|
|
Diastolic Blood Pressure (DBP)
Ramy czasowe: Baseline; Immediate post-intervention (approx. 12 weeks); 6 months post-intervention; 12 months post-intervention
|
Blood pressure was measured with a digital blood pressure device with the participant seated and arm elevated to place the cuff approximately at heart height.
Two blood pressure measurements were taken, waiting at least one minute between readings.
If there was a >5mmHg difference between the first and second reading, an additional two measurements were taken.
The mean of the two (or four) measurements was recorded and used in analysis.
|
Baseline; Immediate post-intervention (approx. 12 weeks); 6 months post-intervention; 12 months post-intervention
|
|
Total Cholesterol
Ramy czasowe: Baseline; Immediate post-intervention (approx. 12 weeks); 6 months post-intervention; 12 months post-intervention
|
Through finger prick blood collection, point of care tests were used to collect lipids using a commercial lipid panel kit and Cholestech LDX analyzer.
|
Baseline; Immediate post-intervention (approx. 12 weeks); 6 months post-intervention; 12 months post-intervention
|
|
High-Density Lipoproteins (HDL)
Ramy czasowe: Baseline; Immediate post-intervention (approx. 12 weeks); 6 months post-intervention; 12 months post-intervention
|
Through finger prick blood collection, point of care tests were used to collect HDL using a commercial lipid panel kit and Cholestech LDX analyzer.
|
Baseline; Immediate post-intervention (approx. 12 weeks); 6 months post-intervention; 12 months post-intervention
|
|
Low-Density Lipoproteins (LDL)
Ramy czasowe: Baseline; Immediate post-intervention (approx. 12 weeks); 6 months post-intervention; 12 months post-intervention
|
Through finger prick blood collection, point of care tests were used to collect LDL using a commercial lipid panel kit and Cholestech LDX analyzer.
|
Baseline; Immediate post-intervention (approx. 12 weeks); 6 months post-intervention; 12 months post-intervention
|
|
Triglycerides
Ramy czasowe: Baseline; Immediate post-intervention (approx. 12 weeks); 6 months post-intervention; 12 months post-intervention
|
Through finger prick blood collection, point of care tests were used to collect triglycerides using a commercial lipid panel kit and Cholestech LDX analyzer.
|
Baseline; Immediate post-intervention (approx. 12 weeks); 6 months post-intervention; 12 months post-intervention
|
|
Glucose
Ramy czasowe: Baseline; Immediate post-intervention (approx. 12 weeks); 6 months post-intervention; 12 months post-intervention
|
Through finger prick blood collection, point of care tests were used to collect random (non-fasting) blood glucose.
|
Baseline; Immediate post-intervention (approx. 12 weeks); 6 months post-intervention; 12 months post-intervention
|
|
Diabetes Self-Efficacy (DMSES)
Ramy czasowe: Baseline; Immediate post-intervention (approx. 12 weeks); 6 months post-intervention; 12 months post-intervention
|
The Diabetes Management Self-Efficacy Scale (DMSES) was used to measure patient's confidence in managing their diabetes.
The DMSES assesses self-reported confidence in managing multiple aspects of their diabetes.
The item reponses range from 1 (not at all confident) to 10 (totally confident) and are averaged to generate composite scores, with higher scores indicating higher levels of self-efficacy.
|
Baseline; Immediate post-intervention (approx. 12 weeks); 6 months post-intervention; 12 months post-intervention
|
|
Diabetes-Related Distress (PAID-5)
Ramy czasowe: Baseline; Immediate post-intervention (approx. 12 weeks); 6 months post-intervention; 12 months post-intervention
|
The Problem Areas in Diabetes scale (PAID-5) was used to measure diabetes-related distress.
The PAID-5 consists of 5 items to assess self-reported diabetes-related emotional distress, including feeling scared or depressed.
Item responses range from 0 (not a problem) to 4 (serious problem) and are summed to produce an overall composite score, with a total score of 8 or higher indicating possible diabetes-related emotional distress.
|
Baseline; Immediate post-intervention (approx. 12 weeks); 6 months post-intervention; 12 months post-intervention
|
|
Food Insecurity
Ramy czasowe: Baseline; Immediate post-intervention (approx. 12 weeks); 6 months post-intervention; 12 months post-intervention
|
Food insecurity was assessed using the 2-item Hunger Vital Sign.
Affirmative answers ("Often True" or "Sometimes True") to either of the 2 screener items indicates food insecurity.
Food insecurity was treated as a binary outcome (0=food secure, 1=food insecure).
|
Baseline; Immediate post-intervention (approx. 12 weeks); 6 months post-intervention; 12 months post-intervention
|
Współpracownicy i badacze
Sponsor
Współpracownicy
Śledczy
- Główny śledczy: Pearl A McElfish, PhD, University of Arkansas
Publikacje i pomocne linki
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Rzeczywisty)
Zakończenie podstawowe (Rzeczywisty)
Ukończenie studiów (Rzeczywisty)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
Dodatkowe istotne warunki MeSH
Inne numery identyfikacyjne badania
- 261074
- 5R01NR019487 (Grant/umowa NIH USA)
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .